Every quarter Lumida Wealth presents a visual summary of the 45+ hedge funds we track every quarter that shape the future investing trends.
Enjoy the visual summary below or Check out the full data along with Ram’s insights in spreadsheet format here.
Please note:
– AUM indicates assets under management in managed 13F securities only, the overall AUM due to other positions (Debt, options etc) may be higher.
– Color intensity indicates relative weight.
– Individual stock Rectangles optimized for mobile readability and are not to scale
– Percentages are rounded to nearest decimal and indicate current portfolio weights
– We have prioritized top 5 stock positions wherever available.
– Each manager has a summary, sector analysis and legend for stock information.
Compliance Disclaimer: The information is for general informational purposes only and does not constitute investment advice. Past performance is not indicative of future results, and investments in hedge funds carry risks, including the potential loss of principal. We recommend that you seek independent financial advice before making any investment decisions.
Data Sources: Hedgefollow, Whalewisdom, Lumida analysis
Summary Overview
RA Capital Management, led by Peter Kolchinsky, focuses heavily on the healthcare sector, particularly in biotechnology and pharmaceuticals. The fund’s top holdings include significant investments in companies developing innovative therapies, while recent activity shows new investments in emerging biotech firms, alongside reductions in existing biotech positions.
3 sector-specific insights
- The top holdings reflect a strong emphasis on biotechnology, with major investments in companies like Ascendis Pharma and Janux Therapeutics.
- New investments in emerging biotech firms suggest a strategic interest in innovative therapies and cutting-edge research.
- Reductions in existing biotech holdings indicate a rebalancing or profit-taking strategy.
Top 5 holdings, additions, and reduced positions
- RYTM (Rhythm Pharmaceuticals, Inc.): Healthcare sector, focuses on developing and commercializing therapies for rare genetic disorders of obesity.
- LEGN (Legend Biotech Corporation): Healthcare sector, engages in the discovery and development of novel cell therapies for oncology and other indications.
- JANX (Janux Therapeutics, Inc.): Healthcare sector, develops next-generation therapeutics for cancer treatment.
- PCVX (Vaxcyte, Inc.): Healthcare sector, focuses on developing vaccines to prevent or treat infectious diseases.
- ASND (Ascendis Pharma A/S): Healthcare sector, develops therapies for endocrinology rare diseases.
New Holdings
- NRIX (Nurix Therapeutics, Inc.): Healthcare sector, focuses on the discovery and development of therapies that modulate protein levels.
- TRML (Tremont Mortgage Trust): Financial sector, focuses on originating and investing in first mortgage loans secured by middle market and transitional commercial real estate.
- ACLX (Arcellx, Inc.): Healthcare sector, develops cell therapies for cancer treatment.
- RXRX (Recursion Pharmaceuticals, Inc.): Healthcare sector, uses machine learning and automation to discover new therapeutic candidates.
- ARTV (Artiva Biotherapeutics, Inc.): Healthcare sector, develops off-the-shelf natural killer (NK) cell therapies for cancer.
Reduced Holdings
- CYBN (Cybin Inc.): Healthcare sector, focuses on psychedelic therapeutics for mental health disorders.
- CRVO (Corvus Pharmaceuticals, Inc.): Healthcare sector, develops immuno-oncology therapies.
- ITOS (iTeos Therapeutics, Inc.): Healthcare sector, focuses on the discovery and development of immuno-oncology therapeutics.
- FULC (Fulcrum Therapeutics, Inc.): Healthcare sector, develops therapies to treat genetically defined rare diseases.
- APGE (Apogee Therapeutics, Inc.): Healthcare sector, focuses on developing therapies for immunological and inflammatory diseases.
